BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zirdafulven readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zirdafulven\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07431216-2597@assetmemo.bio
DTSTAMP:20261121T005350Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Zirdafulven: Phase 1/2 readout est. (NCT07431216)
DESCRIPTION:Zirdafulven\, phase 1/2.\nStudy: A Phase 1b/2a Study to Evaluat
 e the Safety\, Pharmacokinetics\, and Objective Response of STAR-001 (LP-1
 84) in Combination With Spironolactone in Supratentorial Glioblastoma at F
 irst Progression\nEstimated primary completion: 1 May 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/zirdafulven#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07431216
URL:https://assetmemo.bio/drug/zirdafulven#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
